Silexion Therapeutics Corp Stock Price, News & Analysis

Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology through its collaboration with Evonik, developing a long-acting PLGA microparticle formulation for SIL-204, its next-generation siRNA candidate targeting KRAS mutations. Preclinical studies demonstrated high efficacy in reducing tumor size in KRAS-mutated pancreatic cancer models.

The company's RNAi approach silences KRAS mutations at the genetic level, targeting a broader range of mutations (pan-G12x and G13D) with potential applications in pancreatic, colorectal, and lung cancers. This advancement comes amid surging oncology M&A activity, exemplified by Pfizer's $43 billion Seagen acquisition and AbbVie's $10.1 billion Immunogen purchase.

The KRAS inhibitor market is projected to grow at 36% CAGR, reaching $10 billion by 2032. Silexion aims to advance SIL-204 into Phase 2/3 trials by 2025-2026.

Silexion Therapeutics (NASDAQ: SLXN) has announced its collaboration with Evonik for developing an advanced siRNA formulation for cancer treatment. The partnership focuses on creating a long-acting siRNA PLGA microparticle formulation for SIL-204, Silexion's next-generation siRNA candidate.

The formulation, utilizing Evonik's proprietary biodegradable RESOMER® technology, has shown high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. The collaboration aims to enhance cancer treatment through sustained-release RNAi therapy, specifically targeting KRAS mutations, a significant challenge in oncology.

Silexion Therapeutics (NASDAQ: SLXN) has appointed Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics, will serve on the company's audit, compensation, and nominating and corporate governance committees. The appointment strengthens Silexion's scientific expertise as it develops RNA interference (RNAi) therapies for KRAS-driven cancers.

The Board unanimously approved his appointment, citing his extensive experience in advancing novel cancer therapies from discovery to FDA approval. The appointment also ensures Silexion's compliance with Nasdaq's listing requirements by maintaining a fully constituted audit committee.

Silexion Therapeutics (NASDAQ: SLXN) announced a 1-for-9 reverse share split of its ordinary shares, effective after market close on November 27, 2024. Trading on a split-adjusted basis will begin on November 29, 2024, under the same ticker symbol. The par value will increase from $0.0001 to $0.0009 per share, with fractional shares rounded up to whole shares. The move aims to maintain Nasdaq listing compliance and address short-term share price volatility following their business combination. Shareholders with book-entry shares or holding through brokers need not take action as adjustments will be automatic.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on developing RNA interference therapies for KRAS-driven cancers, has announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference. The event will take place December 3-4, 2024, in Boca Raton, Florida.

CEO Ilan Hadar will present "Transforming Cancer Care: Silexion Therapeutics' Innovative Approach to Pancreatic Cancer" on December 4 at 11:30 am. A replay will be available on the company's website. Management will also be available for one-on-one meetings with interested investors during the conference.

Silexion Therapeutics (NASDAQ: SLXN) has reported significant breakthroughs in preclinical studies for its second-generation siRNA candidate, SIL-204. The latest findings show that the SIL-204-microparticle formulation can inhibit growth and induce necrosis in human pancreatic cell lines with the KRAS G12D mutation, which represents the largest segment of pancreatic cancer subtypes.

Key findings include substantial tumor reduction in mouse xenograft studies with a single administration of SIL-204 encapsulated in an extended-release formulation, and a superior extended-release profile resulting from the transition to PLGA microparticles. Silexion plans to initiate toxicology studies soon and aims to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC).

Silexion Therapeutics (NASDAQ: SLXN) has announced significant new data from its Phase 2 trial of LODER™ in non-resectable locally advanced pancreatic cancer (LAPC) patients with KRAS G12D or G12V mutations. The updated analysis shows:

• A 56% objective response rate (ORR) in patients treated with LODER
• ORR increasing to 67% in patients whose tumors became resectable
• A 9.3-month improvement in overall survival compared to chemotherapy alone

The company is also developing SIL-204, a next-generation product targeting a broader range of KRAS mutations, with improved stability and enhanced ability to silence the KRAS oncogene. These findings validate Silexion's oncogene silencing approach in KRAS-driven cancers.

Silexion Therapeutics (NASDAQ: SLXN) is emerging as a disruptive player in precision oncology, developing RNAi therapies for KRAS-driven cancers. Their proprietary LODER™ platform has shown promising results in Phase 2 trials for locally advanced pancreatic cancer, demonstrating a 9.3-month improvement in overall survival when combined with standard chemotherapy.

Silexion's second-generation product, SIL-204, targets a broader range of KRAS mutations and is set to enter Phase 2/3 trials in 2025-2026. The company's innovative approach addresses key challenges in pancreatic cancer treatment, including late detection, aggressive tumor growth, and drug resistance.

With the global precision medicine market projected to reach $470.53 billion by 2034, Silexion's focus on KRAS-driven cancers positions it as a potential acquisition target in a landscape of increasing M&A activity in the oncology space.

Silexion Therapeutics Corp. (SLXN), a clinical-stage oncology-focused biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

Key points:

• Company presentation will be available on-demand starting September 9 at 7:00 AM ET
• Management team will be available for one-on-one meetings during the conference
• Investors interested in meetings should contact their H.C. Wainwright representative
• A replay of the presentation will be accessible on Silexion's website for 90 days

This conference provides Silexion an opportunity to showcase its progress and engage with potential investors in the oncology therapeutics sector.